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ABSTRACT
Although it is well established that hepatitis C virus (HCV) entry into hepatocytes depends on clathrin-mediated endocytosis,
the possible roles of clathrin in other steps of the viral cycle remain unexplored. Thus, we studied whether cell culture-derived
HCV (HCVcc) exocytosis was altered after clathrin interference. Knockdown of clathrin or the clathrin adaptor AP-1 in HCVcc-
infected human hepatoma cell cultures impaired viral secretion without altering intracellular HCVcc levels or apolipoprotein B
(apoB) and apoE exocytosis. Similar reductions in HCVcc secretion were observed after treatment with specific clathrin and dy-
namin inhibitors. Furthermore, detergent-free immunoprecipitation assays, neutralization experiments, and immunofluores-
cence analyses suggested that whereas apoE associated with infectious intracellular HCV precursors in endoplasmic reticulum
(ER)-related structures, AP-1 participated in HCVcc egress in a post-ER compartment. Finally, we observed that clathrin and
AP-1 knockdown altered the endosomal distribution of HCV core, reducing and increasing its colocalization with early endo-
some and lysosomemarkers, respectively. Our data support a model in which nascent HCV particles associate with apoE in the
ER and exit cells following a clathrin-dependent transendosomal secretory route.
IMPORTANCE
HCV entry into hepatocytes depends on clathrin-mediated endocytosis. Here we demonstrate for the first time that clathrin also
participates in HCV exit from infected cells. Our data uncover important features of HCV egress, which may lead to the develop-
ment of new therapeutic interventions. Interestingly, we show that secretion of the very-low-density lipoprotein (VLDL) compo-
nents apoB and apoE is not impaired after clathrin interference. This is a significant finding, since, to date, it has been proposed
that HCV and VLDL follow similar exocytic routes. Given that lipid metabolism recently emerged as a potential target for thera-
pies against HCV infection, our data may help in the design of new strategies to interfere specifically with HCV exocytosis with-
out perturbing cellular lipid homeostasis, with the aim of achieving more efficient, selective, and safe antivirals.
Several cellular factors have been described as mediators of hep-atitis C virus (HCV) assembly, including components of the
very-low-density lipoprotein (VLDL) synthesis machinery (1).
Indeed, nascent virions are thought to exit the infected hepatocyte
by traveling along the secretory pathway tightly linked to VLDL
exocytosis. This is based on the observation that around 40% of
HCV RNA in plasma samples from infected patients is found in a
low-density fraction in association with triglyceride-rich lipopro-
teins containing apolipoprotein B (apoB) and apoE (2). Concor-
dantly, it is well established that apoE is essential for cell culture-
derived HCV (HCVcc) assembly and egress (3). Furthermore,
apoE has been shown to interact with HCVcc, being an important
determinant of HCVcc infectivity (4). In addition, it has been
suggested that microsomal triglyceride transfer protein (MTP)
and apoB also participate in HCVcc morphogenesis and secretion
(5), although these data remain controversial (6). In sum, al-
though it is widely accepted that HCV and VLDL morphogenesis
pathways are connected, the mechanisms by which apoB and
apoE modulate HCV assembly are still poorly understood. Addi-
tionally, although it has been proposed that nascent virions travel
along the Golgi apparatus, early endosomes, late endosomes, re-
cycling endosomes, and secretory vesicles (7, 8), the mechanisms
that regulate such exocytic processes have not been deciphered
so far.
Clathrin mediates the sorting of membrane proteins in the
endocytic and secretory pathways at the plasma membrane, endo-
somal membranes, and trans-Golgi network (TGN) (9). Clathrin-
mediated protein transport is achieved through the action of mul-
tiple adaptors, including AP-1 and AP-2. Whereas AP-1 mediates
the delivery of proteins to the plasma membrane, AP-2 is involved
in endocytic processes (10). On the other hand, clathrin is essen-
tial for both the entry and secretion of some viruses into/from host
cells (11–13). Although it is known that HCV entry is a clathrin-
mediated process (14, 15), the possible role of clathrin in other
steps of the HCV cycle has not been studied. In this study, we
uncovered a role for clathrin in HCV egress. Our results suggest
that AP-1 participates in HCV egress in a post-endoplasmic retic-
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ulum (post-ER) compartment and that clathrin interference re-
sults in the redistribution of HCV core from early endosomes to
lysosomes.
MATERIALS AND METHODS
Cell culture.The human hepatocyte-derived cell lines Huh7 (JCRB-0403)
and Huh7 Lunet N (16) were grown as previously reported (17). The
full-length HCV replicon-containing clone HCV-G5 was generated and
cultured as previously described (17). For hepatocyte-like polarized cul-
tures, we employed Matrigel-based three-dimensional (3D) spheroids as
previously described (18), with minor modifications. One-hundred-mi-
croliter aliquots of 50% Matrigel (BD Biosciences) diluted in complete
medium were deposited into either 8-well chambered cover glasses (Nalge
Nunc International) or 48-well plates (Corning Incorporated) and incu-
bated at 37°C for 30 min. Cells were plated on top of the gel and processed
as indicated. Hepatocyte-like polarity was confirmed by immunofluores-
cence and confocal microscopy analyses as described previously (18).
HCVcc infection and harvest. JFH-1 HCVcc was produced as previ-
ously described (17) and expanded in culture for several passages. For
HCVcc infection of conventional cultures, 105 cells were seeded into
6-well plates and, 24 h later, infected at a multiplicity of infection (MOI)
of 0.01. For some experiments, conditions were scaled to different plate
sizes. At 3 days postinfection, the medium was changed or cells were
transfected with small interfering RNAs (siRNAs) (see below). After 2
days, cells were washed and incubated in fresh medium for 6 h. Where
indicated, 50 M Pitstop2 (Abcam), 80 M dynasore, or 1 g/ml brefel-
din A (BFA) (Sigma) was added during the indicated time before process-
ing of cells and supernatants. The Pitstop2 dose was chosen based on the
50% inhibitory concentration (IC50) (15 M) for transferrin internal-
ization inhibition (19). The dynasore and BFA doses employed here have
been used successfully previously (5, 20). 3D-cultured cells were infected
as previously described (18).
HCVcc production in Huh7 Lunet N cells. A total of 4  106 Huh7
Lunet N cells were electroporated with 5g JFH-1 RNA at 975F and 270
V as previously described (17) and then seeded into 10-cm dishes. After 24
h, cells were trypsinized and reseeded in 6-well plates (3  105 cells per
well). For pharmacological inhibition experiments, cells were treated 2
days after reseeding, and HCVcc was collected as described above. For
siRNA experiments, cells were transfected with the indicated siRNAs 8 h
after reseeding, and HCVcc was harvested 2 days later, as described above.
For immunofluorescence assays, cells were reseeded on coverslips, fixed
or lysed 2 days after siRNA transfection, and processed as described below.
siRNA transfection. Cells were transfected at 3 days postinfection
with 200 nM ON-TARGETplus SMARTpool siRNAs against the human
clathrin heavy chain (CHC), the AP-1 gamma subunit (AP1G1), the AP-2
medium subunit (AP2M1), apoB, or apoE. Alternatively, cells were trans-
fected with individual siRNAs (200 nM) against the clathrin heavy chain.
Control cells were transfected with the same amount of ON-TARGETplus
nontargeting pool or a single control siRNA (Dharmacon). siRNAs and 4
l Dharmafect 1 (Dharmacon) were diluted in 0.75 ml antibiotic-free
Opti-MEM I (Gibco) in separate tubes. After a 5-min incubation at room
temperature, both dilutions were mixed and incubated for an additional
20 min at room temperature. The transfection mix was then supple-
mented with 10% fetal calf serum and added to cells grown in 6-well
plates. For some experiments, conditions were scaled to different plate
sizes. After an overnight incubation at 37°C, the transfection mix was
replaced with complete medium. Two days after transfection, knockdown
efficiency was determined by Western blotting, and cells and supernatants
were processed as indicated.
Determinations of HCV RNA level and infectivity. For intracellular
HCV RNA quantification, RNA extraction, reverse transcription (RT),
and real-time PCR were performed as previously described (17). Extra-
cellular HCV RNA was measured similarly, but employing TRIzol LS
reagent (Ambion) for RNA extraction and adding an overnight RNA pre-
cipitation step at 20°C in the presence of 20 g of glycogen (Roche).
Intracellular infective particles were extracted by four freeze-thaw cycles
as previously described (21). Titrations of both extracellular and intracel-
lular infectivities were carried out by infection of 2  104 Huh7 cells
grown in 48-well plates with diluted supernatants and lysates, respec-
tively, followed by RNA extraction at 3 days postinfection, RT, and real-
time PCR.
Western blots and ELISAs. Western blotting was carried out as pre-
viously described (17), using the following antibodies: rabbit anti-clathrin
heavy chain, mouse anti-alpha 1 antitrypsin (anti-1AT), rabbit anti-
LAMP1 (Abcam), rabbit anti-EEA1 (Cell Signaling Technology), mouse
anti-p53, mouse anti-HCV core (C7-50) (Santa Cruz Biotechnology),
mouse anti-AP1G1, mouse anti-AP50 (AP-2 medium subunit) (BD
Transduction Laboratories), goat anti-apoB, and goat anti-apoE (Calbi-
ochem). Human apoB and apoE enzyme-linked immunosorbent assay
(ELISA) kits (Abnova) were used as recommended by the manufacturer,
using supernatants from siRNA- or inhibitor-treated cells that were har-
vested as described above.
Immunofluorescence analysis. Cells were grown on coverslips or
Matrigel and infected as described above. Transfection with siRNAs was
performed where indicated. Immunofluorescence and confocal micros-
copy analyses were carried out as previously described (17), employing
antibodies against ZO-1 (Life Technologies), HCV core, EEA1, LAMP1,
AP1G1, and apoE. The secondary antibodies used were Alexa 488-conju-
gated goat anti-rabbit or donkey anti-goat and Alexa 647-conjugated goat
anti-mouse antibodies (Molecular Probes, Inc.). For multiple stainings,
samples were incubated sequentially with the indicated primary and sec-
ondary antibodies. Transferrin receptor was detected with a fluorescein
isothiocyanate (FITC)-labeled mouse anti-transferrin receptor (BD
Transduction Laboratories). Confocal microscopy was performed with a
Leica TCS SP5 laser scanning system (Leica Microsystems). For colocal-
ization studies, five x-y optical sections spaced by 0.6 to 0.8 m in the z
axis were acquired from 20 cells (two independent experiments with 10
cells each). Mander’s overlap coefficients for the whole stack of each cell
(fraction of HCV core that colocalized with the AP-1, apoE, EEA1, or
LAMP1 signal) were analyzed using the ImageJ JACop plug-in (22) and
plotted with Graph Pad Prism software.
Proliferation assays. Huh7 cells were grown overnight in 96-well
plates and transfected with control, CHC, or AP-1 siRNAs. Forty-eight or
72 h later, MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo-
lium bromide; Sigma, St. Louis, MO] was added to a final concentration of
0.5 mg/ml in complete RPMI 1640 medium without phenol red. After 3 h
of incubation at 37°C, the medium was removed, and 100l 0.1 N HCl in
absolute isopropanol was added to each well. The absorbance at 570 nm
was measured in a Sunrise Basic Tecan ELISA reader (Tecan Austria
GbmH, Grödig, Austria), and values were interpolated into a standard
curve.
Immunoprecipitation. Protein G Sepharose (GE Healthcare Bio-Sci-
ences AB) was washed three times with phosphate-buffered saline (PBS)
and resuspended in PBS to obtain a 50% slurry. Anti-apoB, anti-apoE
(Calbiochem), or control goat IgG (Santa Cruz Biotechnology) was incu-
bated with the 50% slurry for 30 min at room temperature, with mixing, at
a concentration of 2.5 g antibody per 100 l 50% slurry. Unbound
antibodies were removed by washing three times with cold PBS, and PBS
was added to obtain the antibody-bound 50% slurry. Supernatants and
detergent-free lysates obtained from 6-well plates were diluted 1/5 in
complete medium and precleared with 100 l 50% slurry for 1 h at 4°C,
with mixing. Triplicate aliquots of precleared supernatants or lysates were
used to determine the level of input HCV RNA. Immunoprecipitation was
carried out by incubating 0.5 ml precleared supernatant or lysate with 40
l antibody-bound 50% slurry for 3 h at 4°C, with mixing. Postimmuno-
precipitation supernatants or lysates were used for titration experiments,
and immunoprecipitates were washed three times with cold complete
medium and processed for Western blotting or HCV RNA determination
by using TRIzol LS reagent and glycogen for RNA precipitation (see
above).
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Statistical analysis. Homoscedasticity and normal distribution were
tested and comparison of means analyzed by using one-way analysis of
variance (ANOVA). The Mann-Whitney U test was used under violated
assumptions. All analyses were performed with G-Stat 2.0 software. P
values of 0.05, 0.01, and 0.001 are represented by asterisks (*, **,
and ***, respectively) in the figures.
RESULTS
HCVcc egress is mediated by clathrin, AP-1, and dynamin. We
first addressed whether clathrin and AP-1 are involved in HCVcc
secretion. Huh7 cells were infected with HCVcc at an MOI of 0.01,
and at 3 days postinfection, cells were transfected with siRNA
pools specific for either CHC or the AP-1 gamma subunit. After 2
days, cells were extensively washed and incubated with fresh me-
dium for six additional hours. Extracellular HCV RNA levels and
infectivity were significantly reduced after CHC and AP-1 knock-
down, whereas intracellular HCV levels were not significantly al-
tered (Fig. 1A and B). Similar results were obtained using four
different individual siRNAs against CHC (Fig. 1C and D). We
noted that CHC and AP-1 knockdown did not induce any altera-
tion in cell proliferation or HCV RNA replication (Fig. 1E and F).
Furthermore, we observed no reduction in either HCV core ex-
pression levels or the number of viral protein-positive cells after
CHC or AP-1 knockdown at the time point when cells and super-
natants were processed (Fig. 1G and H), strongly suggesting that
the differences observed in extracellular infectivity and HCV RNA
levels were not due to a reduction of viral replication or an im-
paired spread of infection caused by a block of HCVcc entry. To
further support this notion, we studied the roles of clathrin and
AP-1 in HCVcc egress by using Huh7 Lunet N cells (16), into
which HCV RNA was introduced by electroporation. These cells
are able to secrete infective virions but are resistant to secondary
infection due to the lack of the HCV coreceptor CD81 (16). Thus,
they constitute an ideal tool for studying HCVcc exocytosis in a
single round of viral egress. In agreement with the results obtained
with Huh7 cells, CHC and AP-1 knockdown impaired HCVcc
egress without affecting intracellular viral RNA and infectivity lev-
els (Fig. 1I).
Next, we employed a pharmacological approach to study
whether acute clathrin inhibition impaired HCV exocytosis.
Treatment of HCVcc-producing Huh7 Lunet N cells with the
clathrin inhibitor Pitstop 2 (19) significantly reduced HCVcc se-
cretion without altering intracellular viral levels (Fig. 2A). We also
assessed the role of dynamin in HCV egress. Dynamin is a GTPase
essential for membrane fission events during several cellular pro-
cesses that involve vesicle formation (23). Although dynamin’s
best-studied function is its role during clathrin-mediated endocy-
tosis, it has also been shown to participate in trafficking from the
TGN (24). Dynamin inhibition by dynasore treatment (25) signif-
icantly impaired HCVcc egress without reducing intracellular vi-
ral levels (Fig. 2A). Since HCV entry is a clathrin-dependent pro-
cess, we wanted to rule out the possibility that the reduced
extracellular infectivity of inhibitor-treated cells was an artifact
due to the impaired viral entry during titration experiments
caused by inhibitor carryover. Although it was very unlikely, we
considered the most extreme scenario and assumed that 100% of
inhibitor activity was still present in HCVcc-containing superna-
tants after their harvest. We performed infection experiments by
adding 2.5 M Pitstop 2 or 4 M dynasore to HCVcc-containing
supernatants that were generated by infected Huh7 cells in the
absence of inhibitors. The concentrations used were 20-fold lower
than those applied to HCVcc-producing cells (50 M Pitstop 2
and 80 M dynasore), since titration experiments were routinely
carried out using a 1:20 dilution of infective supernatants. Under
these conditions, we observed no impairment of HCVcc infection
(Fig. 2B), thus demonstrating that the effects shown in Fig. 2A
were not due to inhibitor carryover but to defective HCVcc secre-
tion from inhibitor-treated cells. The impairment of HCVcc
egress by Pitstop 2 and dynasore treatment was confirmed in 3D
cultures of hepatocyte-like polarized Huh7 cells (Fig. 2C to E),
which were previously described by our group (18).
The fact that both CHC and AP-1 depletions resulted in similar
blocks of virus production suggested that clathrin-mediated an-
terograde transport was involved in HCVcc egress. However, in
order to confirm that the effects mediated by CHC or dynamin
knockdown and/or inhibition were not due to defective endocytic
processes, we performed the same set of experiments by knocking
down the medium subunit of the clathrin adaptor AP-2, a well-
defined complex that regulates endocytosis of certain plasma
membrane proteins (10) and has been shown to be essential for
endocytic clathrin-coated pit and clathrin-coated vesicle forma-
tion (26, 27). Whereas AP-2 knockdown effectively impaired
transferrin receptor internalization (Fig. 3A and B), extracellular
HCV RNA levels were not reduced (Fig. 3C). Although this result
did not rule out a role of AP-2 in viral particle assembly (see
Discussion), it indicated that viral exit from infected cells was not
compromised after AP-2 knockdown. Collectively, these data
strongly suggest that HCVcc egress depends on exocytic transport
routes that require the concerted action of clathrin, AP-1, and
dynamin.
apoB and apoE secretion is not impaired after clathrin inter-
ference. Since HCV exit from cells has been proposed to be tightly
linked to VLDL secretion (1), we next sought to determine
whether the impairment of HCV egress observed after perturbing
clathrin-mediated trafficking could be due to a defective exocyto-
sis of VLDL-associated proteins. Employing the same experimen-
tal approaches as those described above, we tested the effects of
clathrin and AP-1 knockdown and/or pharmacological inhibition
on apoB and apoE secretion from infected cells. Interestingly, in
contrast to HCV egress, ELISAs and Western blot analyses showed
no significant reduction in apoB and apoE secretion after clathrin
or AP-1 knockdown and/or inhibition in both Huh7 cells (Fig. 4A
to C) and Huh7 Lunet N cells (data not shown). To further con-
firm that clathrin inhibition did not impair apoB and apoE secre-
tion, we performed kinetic assays and observed that the Pitstop
2-induced reduction in viral RNA egress was not paralleled by a
decrease in apoB or apoE secretion at any time point studied (Fig.
4D and E). In contrast, dynamin inhibition impaired both apoB
and apoE exocytosis (Fig. 4C). These results were confirmed in 3D
cultures of hepatocyte-like polarized Huh7 cells (Fig. 2F and G).
We noted that dynasore treatment also prevented1AT secretion,
possibly indicating a broader role of dynamin in general exocytic
processes.
Altogether, these data suggested that whereas HCVcc egress
was a clathrin-, AP-1-, and dynamin-dependent process, secretion
of VLDL-associated proteins was mediated by dynamin but not by
clathrin or AP-1. In agreement with previous reports, apoB (5)
and apoE (3) knockdown inhibited HCVcc assembly and egress
without altering intracellular HCV RNA levels (data not shown).
Hence, these results indicated that whereas apoB and apoE down-
Benedicto et al.
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regulation was detrimental for HCVcc morphogenesis and secre-
tion, the decrease in HCV egress observed after clathrin or AP-1
interference was not due to an impairment of the main exocytic
route followed by these VLDL-associated proteins.
Participation of apoE and AP-1 at different points along the
HCVcc secretory pathway. Our results suggested that HCV hi-
jacked both the VLDL assembly pathway and clathrin-mediated
anterograde traffic during viral egress. However, we found no ev-
FIG 1 HCVcc egress is mediated by clathrin and AP-1. (A) HCV RNA and infectivity quantification after CHC and AP-1 knockdown in infected Huh7 cells.
Results are expressed as means and standard errors of the means (SEM) for at least three experiments performed in triplicate. (B) Western blot analysis of CHC
and AP-1 knockdown efficiencies in Huh7 cells. p53 was used as a loading control. (C) Western blot analysis of HCV core protein levels and CHC knockdown
efficiency after transfection of HCVcc-infected Huh7 cells with either control siRNA, four different CHC-specific siRNAs, or the pooled CHC siRNA mix used
for panel B. p53 was used as a loading control. Numbers indicate the relative intensities of bands compared to those for control cells after being normalized to p53
levels. (D) HCV RNA and infectivity quantification after CHC knockdown. Results are expressed as means and SEM for an experiment performed in triplicate.
(E) Cell proliferation was assessed as described in Materials and Methods. Results obtained 48 h and 72 h after transfection are shown. (F) HCV RNA levels in a
clone containing a full-length HCV replicon were analyzed by real-time RT-PCR. (G) HCV core levels were analyzed by Western blotting. p53 was used as a
loading control. (H) HCV core levels were analyzed by immunofluorescence. Green, HCV core; blue (DAPI [4=,6-diamidino-2-phenylindole]), nuclei. (I) HCV
RNA and infectivity quantification after CHC and AP-1 knockdown in HCVcc-producing Huh7 Lunet N cells. Results are expressed as means and SEM for at
least three experiments performed in triplicate.
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idence supporting a role of clathrin or AP-1 in apoB or apoE
exocytosis. Thus, we hypothesized that HCVcc egress may share
some steps with both VLDL assembly and clathrin-mediated traf-
ficking, but at different points along the secretory pathway. First,
given the controversy regarding apoB association with HCVcc, we
wanted to study HCVcc apolipoprotein composition in our ex-
perimental system. As shown in Fig. 5A to C, apoE but not apoB
was clearly detected as part of the infective viral particle, similar to
previously published data (6, 28). In order to determine the sub-
cellular location of HCVcc and apoE association, we next per-
formed a series of immunoprecipitation experiments using cell
lysates obtained by repeated freeze-thaw cycles. We employed this
FIG 2 HCVcc secretion is impaired after clathrin and dynamin pharmacological inhibition. (A) HCV RNA levels after clathrin or dynamin inhibition in Huh7
Lunet N cells by 50 M Pitstop 2 or 80 M dynasore treatment, respectively. Data are presented relative to those for vehicle-treated control cells. Results are
expressed as means and SEM for four experiments performed in triplicate. (B) Analysis of the possible effects of Pitstop 2 and dynasore carryover during titration
of infective supernatants after inhibitor treatment. (C) Polarized hepatocyte-like localization of ZO-1 in Huh7 cells cultured on Matrigel. Red, ZO-1; blue
(DAPI), nuclei. Bar, 25 m. (D and E) Effects of Pitstop 2 (D) or dynasore (E) treatment on extracellular and intracellular HCV RNA levels in 3D-cultured,
HCVcc-infected Huh7 cells. Results are presented relative to those for vehicle (dimethyl sulfoxide [DMSO])-treated control cells and are expressed as means and
SEM for three experiments. (F and G) Western blot analyses of apoB and apoE levels in supernatants and cellular lysates obtained from 3D-cultured, HCVcc-
infected Huh7 cells after clathrin (F) or dynamin (G) inhibition. 1AT and p53 were used as loading controls.
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detergent-free approach to avoid the possible envelope removal
from the intracellular viral particle (29). As shown in Fig. 5D,
HCV RNA clearly coimmunoprecipitated with apoE above back-
ground levels. In addition, apoE knockdown caused a marked
decrease in the level of coimmunoprecipitated HCV RNA with
the anti-apoE antibody (Fig. 5D). Note that the amount of the
cellular histone H3 RNA that coimmunoprecipitated with apoE
was indistinguishable from background levels, regardless of apoE
knockdown (Fig. 5D). These results indicated that HCV RNA spe-
cifically coimmunoprecipitated with intracellular apoE. Next, we
repeated these experiments but treated cells with brefeldin A
(BFA), a drug that inhibits ER-to-Golgi traffic (30). As previously
reported (5), BFA treatment of infected cells caused marked re-
ductions in secreted HCV RNA and extracellular infectivity,
which were accompanied by2-fold increases in both intracellu-
lar viral RNA and infectivity (Fig. 5E). Interestingly, detergent-
free immunoprecipitation assays after BFA treatment showed a
proportional accumulation of intracellular apoE-associated HCV
RNA (Fig. 5F, left panel). Importantly, intracellular infectivity of
BFA-treated cells was reduced after apoE immunoprecipitation
(Fig. 5F, right panel), suggesting that apoE was associated with
infectious HCV precursors in ER-related compartments. This no-
tion was supported by the neutralization of intracellular HCV
virions from BFA-treated cells with an anti-apoE antibody previ-
ously shown to partially block HCVcc infection (4) (Fig. 5G).
These results strongly suggested that apoE interaction with the
virion occurred, at least in part, before it left the ER, as previously
postulated by others (1).
We next sought to determine whether clathrin-mediated traf-
fic participated in HCV egress before or after the virion exited the
ER. To that end, we treated HCVcc-producing Huh7 Lunet N cells
with BFA and performed immunofluorescence assays to study the
colocalization between HCV core and AP-1. A similar imaging
approach was used previously to assess the impact of inhibiting
endosomal movement on HCVcc secretion (7). Since BFA treat-
ment induces the accumulation of secreted cargoes in the ER, we
hypothesized that if the nascent virion interacted with AP-1 before
exiting the ER, blocking ER-to-Golgi traffic by BFA treatment
would induce the accumulation of AP-1-positive viral particles in
the ER, resulting in an increased colocalization between core and
AP-1. On the other hand, if the virion interacted with AP-1 in a
post-ER compartment, BFA treatment would prevent the exit of
the virion from the ER, thus precluding its interaction with AP-1.
Interestingly, BFA treatment resulted in a decreased colocaliza-
tion between core and AP-1 (Fig. 6A), suggesting that the interac-
tion of AP-1 with the viral particle takes place in a post-ER
compartment. Conversely, BFA induced an increase in the colo-
calization between core and apoE (Fig. 6B). This result is in agree-
ment with the data shown in Fig. 5F and G indicating that the
interaction between apoE and the nascent virion takes place be-
FIG 3 HCV exocytosis is not mediated by AP-2. (A) Western blot analysis of
AP-2 knockdown efficiency. p53 was used as a loading control. (B) Immuno-
fluorescence analysis of transferrin receptor localization after AP-2 knock-
down. Bar, 25 m. (C) HCVcc-infected cells were transfected with control or
AP-2-specific siRNAs, and HCV RNA levels in supernatants were quantified
by real-time RT-PCR. Results are presented relative to those for control
siRNA-transfected cells and are expressed as means and SEM for six experi-
ments performed in triplicate.
FIG 4 apoB and apoE secretion is not impaired by clathrin or AP-1 interference. (A and B) apoB and apoE levels were determined by ELISA (A) and Western
blotting (B) after CHC or AP-1 knockdown in infected Huh7 cells. 1AT and p53 were used as loading controls. (C) apoB and apoE levels in the supernatants
of infected Huh7 cells after 50 M Pitstop 2 or 80 M dynasore treatment were determined by ELISA. Results are expressed as means and SEM for two
experiments performed in duplicate. (D and E) Kinetic analyses of secreted apoB, apoE, and 1AT (D) and of secreted HCV RNA (E) by Western blotting and
real-time RT-PCR, respectively, after Pitstop 2 treatment of infected Huh7 cells. Results in panel E are presented relative to the maximum value and expressed
as means and SEM for three experiments.
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fore its exit from the ER. Collectively, these results suggest that
apoE and AP-1 interact with the nascent virion before and after its
exit from the ER, respectively.
Clathrin and AP-1 knockdown alters HCV core endosomal
localization. Our data suggested that interfering with clathrin-
mediated anterograde trafficking could block viral egress at the
level of a post-ER compartment. However, we did not detect an
increase in intracellular infectivity after CHC or AP-1 knockdown
(Fig. 1). What happens, then, with the nonsecreted viral particles?
It has been shown that newly formed immature HCVcc particles
are actively degraded in a post-ER cellular compartment and that
only mature, low-density particles escape degradation and un-
FIG 5 Intracellular HCVcc-apoE association in BFA-treated cells. (A) Immunoprecipitation (IP) from supernatants of HCVcc-infected cells, using control,
anti-apoB, and anti-apoE antibodies. apoB and apoE levels were determined by Western blotting (WB). (B) Supernatant infectivity after immunoprecipitation
was analyzed by titration on Huh7 cells and real-time RT-PCR. Results are presented relative to the infectivity of control Ig-immunoprecipitated supernatants
and are expressed as means and SEM for three experiments. (C) Supernatant immunoprecipitation was carried out as described for panels A and B, and RNAs
were extracted from both immunoprecipitates and postimmunoprecipitation supernatants. HCV RNA levels were assessed by real-time RT-PCR and presented
as percentages of input HCV RNA. Results are expressed as means and SEM for three experiments. (D) Immunoprecipitates from detergent-free lysates of
HCVcc-infected, siRNA-transfected cells were used for either Western blot analysis (inset; control siRNA-transfected cells) or HCV RNA quantification. (E)
HCV RNA levels and infectivities after 1 g/ml BFA treatment. (F) (Left) Immunoprecipitated HCV RNA levels after BFA treatment. (Right) Intracellular
infectivities of BFA-treated cells after immunoprecipitation. (G) Intracellular infectivities of BFA-treated cells, assessed by titration on Huh7 cells in the presence
of 5 g/ml control or anti-apoE antibody. Results are expressed as means and SEM for at least three experiments.
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dergo exocytosis (5). Thus, we hypothesized that if the exocytic
route followed by mature viral particles was blocked by interfering
with clathrin-mediated trafficking, those virions could be diverted
toward degradation, possibly at the lysosomes. Since inhibition of
endosomal movement results in the accumulation of HCV core at
early endosomes and in impaired viral secretion, it has been pro-
posed that HCV particles traffic through early endosomes before
exiting the cell (7). Thus, we studied the colocalization of HCV
core and either the early endosome marker EEA1 or the lysosome
marker LAMP1 after CHC or AP-1 knockdown in HCVcc-pro-
ducing Lunet N cells. As shown in Fig. 7A, both CHC and AP-1
knockdowns induced decreases in the colocalization between
HCV core and EEA1. Conversely, CHC or AP-1 knockdown re-
sulted in increased colocalization between the viral protein and
LAMP1. Note that CHC or AP-1 knockdown did not alter HCV
core, EEA1, or LAMP1 protein levels as determined by Western
blotting (Fig. 7B). These results demonstrated that clathrin and
AP-1 knockdown impaired the normal endosomal localization of
HCV core, suggesting an altered transendosomal exocytic HCVcc
pathway that results in the lysosomal disassembly of some of the
mature viral progeny.
DISCUSSION
Herein we demonstrated a role for clathrin and its adaptor AP-1 in
HCVcc egress, which could not be attributed to impaired apoE or
apoB secretion. In addition, biochemical and imaging experi-
ments suggested that apoE and AP-1 participate in HCVcc egress
at different points along the secretory pathway, with AP-1 being
involved in a post-ER transendosomal route that enables the vi-
rion to exit the cell, escaping from lysosomal disassembly.
Several studies have followed knockdown approaches to assess
the roles of clathrin and its adaptors in protein sorting (31–33).
Notably, the magnitudes of the effects observed did not quantita-
tively match the strong knockdown efficiencies achieved. Simi-
larly, the impairment of HCV egress we detected after clathrin or
AP-1 interference was moderate. This can be explained by the fact
that residual amounts of the knocked-down protein may be suf-
ficient to partially enable the studied process. Alternatively, as
shown for LDL uptake in lipoprotein-starved AP-2-depleted cells
(26, 27), inhibition of a trafficking pathway might lead to the
acquisition of a surrogate route, which may partially mask the
experimental readout. Nevertheless, our results obtained follow-
ing different approaches to interfere with clathrin and AP-1
(siRNA and chemical inhibition) in several culture systems (Lunet
N and 2D- and 3D-cultured Huh7 cells) were consistent, strongly
suggesting a role for clathrin and AP-1 in HCV exocytosis.
The aforementioned reports (31–33) showed that in polarized
epithelial cells, clathrin and AP-1 participate in trafficking path-
ways followed by basolateral membrane proteins from both the
TGN and recycling endosomes to the plasma membrane. Thus, it
is plausible that nascent virions interact with such a protein within
the cell en route to the plasma membrane, during either biosyn-
thetic or recycling transport, to facilitate viral egress. Interestingly,
knockdown approaches and live-cell imaging experiments have
suggested that both TGN and recycling endosome proteins medi-
ate HCV exocytosis (8). Additionally, depletion of the Golgi-spe-
cific phosphatidylinositol 4-phosphate pool has been shown to
impair HCV secretion (34). Although our data suggest that the
involvement of AP-1 in HCV egress takes place in a post-ER com-
partment, further studies will be needed to more precisely address
the subcellular compartment(s) where clathrin exerts its role in
HCV exocytosis and to investigate the possible participation of a
cellular protein as a “carrier” during viral secretion.
There are several examples in the literature showing that pertur-
bation of the traffic routes followed by different cellular proteins can
impair viral egress and induce the accumulation of viral structural
proteins in lysosomal compartments. Inhibition of N-glycan process-
FIG 6 Colocalization of HCV core with AP-1 and apoE after BFA treatment. HCVcc-producing Huh7 Lunet N cells were treated with 1 g/ml BFA for 6 h and
fixed for further immunofluorescence analysis. Green, HCV core; red, AP-1 (A) or apoE (B); blue (DAPI), nuclei. Images show a single x-y section from the
confocal stack of a representative cell. The red box shows a detail of the merged image. Bars, 10m. In the scatterplots, each dot represents Mander’s coefficient
for HCV core (fraction of HCV core that colocalizes with AP-1 or apoE) for each of the 20 cells from two independent experiments (see Materials and Methods
for details). The horizontal lines represent median Mander’s coefficients for all cells studied.
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ing, which results in the defective trafficking and secretion of certain
glycoproteins, was shown to inhibit viral DNA secretion and to in-
duce the accumulation of hepatitis B virus structural proteins within
lysosomal compartments (35). Another interesting example is
Niemann-Pick type C-1-deficient cells, in which cholesterol and cel-
lular proteins accumulate in late endosomal/lysosomal compart-
ments. After human immunodeficiency virus type 1 infection, the
viral capsid protein fails to traffic properly and also accumulates
within these compartments, resulting in a decreased release of infec-
tious particles (36). In this context, one possibility is that the lyso-
somal accumulation of HCV core after CHC or AP-1 knockdown
represents a failure of HCVcc assembly, with the viral protein reach-
ing the lysosome before being assembled into the capsid of a nascent
virion. However, the fact that blocking ER-to-Golgi traffic by BFA
treatment induces the intracellular accumulation of infective viral
particles strongly suggests that capsid assembly takes place before the
virion exits the ER. Since AP-1 is localized at the TGN and recycling
endosomes (i.e., post-ER compartments) and AP-1 colocalization
with HCV core is reduced upon BFA treatment, it is not likely that
AP-1 knockdown interferes with HCV capsid assembly. Another
possibility is that lysosomal HCV core accumulation after CHC or
AP-1 interference represents an endpoint of the nascent virion after
being diverted from the TGN or recycling endosomes during its nor-
mal secretory route. Undoubtedly, live-cell imaging experiments
studying HCV core trafficking (8) would be very helpful for testing
these hypotheses. Additionally, elucidating the cellular exocytic traf-
ficking pathways altered after CHC or AP-1 knockdown may help to
assess these and other possible scenarios.
FIG 7 Colocalization of HCV core with EEA1 and LAMP1 after CHC or AP-1 knockdown. (A) HCVcc-producing Huh7 Lunet N cells were transfected with
control, CHC, or AP-1 siRNAs and fixed 2 days later for immunofluorescence analysis. Green, HCV core; red, EEA1 (left) or LAMP1 (right); blue (DAPI), nuclei.
Images show a single x-y section from the confocal stack of a representative experiment. The red box shows a detail of the merged image. Bars, 10 m.
Quantification and scatterplot representations were performed as described in the legend to Fig. 6 and in Materials and Methods. (B) (Left) Western blot showing
efficiency of CHC or AP-1 knockdown. (Right) Western blot showing unaltered expression levels of EEA1, LAMP1, and core after CHC or AP-1 knockdown.
Numbers indicate the relative intensities of bands compared to those of control cells after being normalized to p53 levels.
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Our data revealed the implication of clathrin in HCVcc secre-
tion but did not rule out additional roles in the assembly process.
Indeed, while our manuscript was in preparation, it was reported
that the clathrin adaptor AP-2 interacts with core and participates
in HCVcc assembly (37). Whereas this observation may represent
a link between clathrin and HCV assembly, it seems to be contra-
dictory with our data regarding AP-2 knockdown. However, the
experimental designs of both studies were notably different. In the
previous work, cells were transfected with HCV RNA after AP-2
depletion. In the present study, cells were first infected and then
transfected with AP-2 siRNA after allowing infection to spread, so
it is possible that the presence of assembled virions prior to the
reduction of AP-2 levels masked assembly defects induced by
AP-2 knockdown. In conclusion, while our experiments did not
show evidence against a role for AP-2 in HCVcc assembly, they
suggest that AP-2 is not involved in the exocytosis of assembled
virions and that clathrin-mediated HCVcc egress is not dependent
on AP-2.
To date, the observed interaction between HCV and apolipo-
proteins both in vitro and in vivo has led to the hypothesis that
HCV may use the VLDL secretory pathway to exit infected cells.
However, our data showing that clathrin and AP-1 interference
prevented HCVcc exocytosis but not apoB and apoE secretion
raise certain doubts about the currently proposed model. Our
results suggest that once the HCV virion is associated with apoE
during its assembly, there is some point along the exocytic route at
which lipoviroparticle egress diverges from normal apoE secre-
tion. Since apoE is a glycosylated protein (38), and given the key
role of glycosylation during polarized exocytosis of certain mem-
brane and soluble proteins (39), it is possible that the virion inter-
action with apoE modifies or masks its glycosylation pattern, thus
altering its normal secretory route. Alternatively, it can also be
hypothesized that viral envelope proteins may direct HCV egress
through interactions with a carrier factor (see above), diverting
virus-associated apolipoproteins from their natural exocytic path-
way. It is worth noting that the amount of virus-associated apoE
would probably be very low compared to that of total secreted
apolipoprotein, in such a way that the reduction of apolipoprotein
secretion caused by the block of lipoviroparticle exocytosis would
presumably be undetectable.
We also point out that clathrin involvement in viral spread
might result in cellular alterations that may lead to pathological
disorders. It has been reported that mammalian reovirus infection
induces clathrin recruitment to viral factories, disrupting cellular
functions such as clathrin-dependent endocytosis and secretion
(40). As the authors of that study argued, inhibition of clathrin-
mediated trafficking routes might impair some aspects of the
innate and adaptive immune responses that depend on vesicle
transport, favoring the persistence of infection. In addition,
virus-induced clathrin interference may cause a loss of epithe-
lial polarization (31) with concomitant pathological conse-
quences, including the enhancement of viral spread (41). Re-
garding HCV infection, the alteration of clathrin-mediated
functions still needs to be addressed. However, it is interesting
that in HCV replicon-containing cells, transport of major his-
tocompatibility complex class I molecules to the cellular sur-
face is inhibited (42), and basolateral membrane proteins are
mislocalized to the apical surface (17). Whether these observa-
tions are mediated by HCV-induced clathrin alterations war-
rants further investigation.
In conclusion, our results showing that clathrin and AP-1 par-
ticipate in HCVcc egress contribute to the understanding of HCV
pathobiology and open a potential new therapeutic avenue for
fighting HCV infection.
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